Reported about 14 hours ago
The article examines Jim Cramer's previous comments on Bristol-Myers Squibb Co. (BMY), where he expressed a preference for Pfizer for yield-focused investors, suggesting BMY would have a long wait for significant returns. Despite Cramer’s cautious outlook, BMY's stock rose by over 15%, outperforming Pfizer. Cramer acknowledges owning BMY in his charitable trust but is hesitant to buy back due to concerns over upcoming patent expirations and mixed results from a key drug study. Overall, the article concludes that while BMY shows potential, other AI stocks might offer better returns.
Source: YAHOO